Claims data indicates use of an oral anticoagulant (e.g., Xarelto or Eliquis) in the treatment of cancer-associated thromboembolism was associated with 50% less VTE recurrence and 60% less death from any cause compared with low-molecular-weight heparin. | Riaz, JAMA Netw Open 2023
